China Drug Delivery Devices Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 9.30 % |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
China Drug Delivery Devices Market Analysis
The China drug delivery devices market is expected to register a CAGR of 9.3% over the forecast period.
- Drug delivery devices were crucial in the early stages of the COVID-19 pandemic as most pharmaceutical companies and governments tried to properly treat COVID-19 patients. For instance, in September 2022, CanSinoBIO received approval for the recombinant COVID-19 vaccine (Convidecia Air) for inhalation delivery in China. Convidecia Air provides a non-invasive option using a nebulizer to change liquid into an aerosol inhalation through the mouth. Thus, the advancements in the delivery of vaccines for COVID-19 significantly impacted the market. However, the market is growing at a stable pace due to a resumption of diagnosis procedures, manufacturing activities, and the availability of products. It is expected to witness a similar trend over the coming years.
- The major factors attributing to the growth of the Chinese drug delivery devices market are the growing burden of chronic diseases and the technological advancements in drug delivery devices. Due to the rising prevalence of chronic diseases, drug delivery systems are becoming more frequently used to enhance patient health and treatment outcomes. For instance, according to the International Diabetes Federation's Diabetes Atlas 2021, in China, there were 140.8 million diabetics in 2021; this number is expected to rise to 164 million by 2030. There is a gradual rise in the prevalence of diabetes in China, which is expected to increase demand for prefilled syringes and autoinjectors during the forecast period.
- Furthermore, as per the article published in the Chinese Medical Journal in March 2022, China is experiencing a greater incidence of cancer. In China, there were about 4.8 million new cases of cancer in 2022, with lung cancer being the most prevalent type. Thus, the greater incidence of cancer has increased the demand for drug-delivery devices. These devices deliver optimal drug doses to targeted cancer sites to enhance drug efficacy and reduce adverse side effects by maintaining drug concentration at a minimum in the targeted cancerous tissues, thereby boosting the market growth.
- The strategic activities by the market players, such as product launches, mergers and acquisitions, and partnerships, are expected to boost the market's growth over the forecast period. For instance, in August 2021, Oyster Point Pharma sold the rights to two nasal sprays for patients with dry eye disease in greater China to Ji Xing Pharmaceuticals for USD 17.5 million upfront. The deal comes ahead of an FDA decision that could make one of the drugs the first nasal spray approved for dry eye disease. Thus, all the aforementioned factors, such as the rising prevalence of chronic diseases and product launches by market players, are expected to boost the market over the forecast period. However, the high cost of development for drug delivery devices may restrain market growth over the forecast period.
China Drug Delivery Devices Market Trends
Auto-Injectors Segment is Expected to Hold the Significant Market Share During the Forecast Period
- The auto-injectors segment is expected to witness significant growth due to collaborations and partnerships among companies for auto-injectors, convenient usage, and the increased burden of chronic diseases. For instance, according to the report published by the National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID) in October 2021, there will be about 5 million rheumatoid arthritis patients in China 2021, with an average onset age of 45 years.
- Hence, for treating chronic diseases, there is a need for self-injectable devices like auto-injectors, which are convenient and easy to use. Thus, the segment drives the growth of the market during the study period.
- The product launches by the market players are expected to propel the growth of the market over the forecast period. For instance, in July 2021, ALK Abello and China Grand Pharma entered an exclusive licensing agreement for adrenaline autoinjector ALK's AAI Jext to launch the product in China.
- Thus, due to the above-mentioned factors, such as the growing burden of chronic diseases and product approvals, the auto-injectors segment is expected to grow significantly during the forecast period.
Pulmonary Disease Segment is Expected to Hold the Significant Market Share During the Forecast Period
Pulmonary disease is a type of disease that affects the lungs and other parts of the respiratory system. Pulmonary diseases may be caused by infection, by smoking tobacco, or by breathing in second-hand tobacco smoke, radon, asbestos, or other forms of air pollution. Some of the most common pulmonary diseases are chronic obstructive pulmonary disease (COPD), asthma, occupational lung diseases, and pulmonary hypertension. The pulmonary drug devices help to inhale through the mouth and deposit in the lower airways. The pulmonary diseases segment is expected to hold a significant market share owing to the rise in prevalence of this disease in the country and demand for the drug-delivery devices.
According to the study published in the Value in Health Regional Issues in November 2022, between 2020 and 2039, it was expected that China would experience a rise in the number of COPD patients from 88.3 million to 103.3 million; this increase would be accompanied by a 31% rise in the number of severe cases. Thus, the significant burden of COPD in the country is expected to propel the growth of the segment over the forecast period.
The technological advancements in drug delivery technology have increased the demand for the management of diseases and, hence, are expected to boost segment growth. According to the study published in the Journal of Bio Integration in November 2021, the use of nano-based delivery systems for pulmonary drug delivery, such as liposomes, micelles, and nanoparticles, has proven to be a successful method for achieving drug deposition and sustained controlled drug release in the lungs. The application of nanotechnology continues to offer several benefits in the treatment of various chronic diseases, such as pulmonary disease, and results in remarkable improvements in treatment outcomes. The study was conducted in China, and the adoption of this technology in drug delivery devices may propel the demand for drug delivery devices over the forecast period. Thus, all the aforementioned factors are expected to boost segment growth over the forecast period.
China Drug Delivery Devices Industry Overview
The China drug delivery devices market is highly competitive and consists of several key players. In terms of market share, few of the major players are currently dominating the market, and some prominent players are vigorously making acquisitions and joint ventures with other companies to consolidate their market positions in the country. Some of the key players include Gerresheimer AG, Pfizer Inc., F. Hoffmann-La Roche AG, Becton, Dickinson and Company, Teva Pharmaceutical Industries Ltd, Merck & Co. Inc., Novartis AG, Sanofi, GSK plc, and Baxter.
China Drug Delivery Devices Market Leaders
Becton, Dickinson and Company
Gerresheimer AG
Pfizer Inc.
Teva Pharmaceutical Industries Ltd
Teleflex Medical
*Disclaimer: Major Players sorted in no particular order
China Drug Delivery Devices Market News
- November 2022: DKSH and Nuance Pharma agreed to market the nasal spray device in Hong Kong and Macau. Based in Shanghai, China, Nuance Pharma reached a major commercial milestone with an agreement to bring a novel nasal spray to market.
- June 2022: EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics received approval from China's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
China Drug Delivery Devices Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Chronic Diseases
4.2.2 Advancement in Technology
4.3 Market Restraints
4.3.1 The High Cost of Development
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Device Type
5.1.1 Nasal
5.1.1.1 Inhalers
5.1.1.2 Other Device Types
5.1.2 Implantable
5.1.3 Injectable
5.1.3.1 Conventional Drug Delivery Devices
5.1.3.2 Self-injectable Drug Delivery Devices
5.1.3.2.1 Prefilled Syringes
5.1.3.2.2 Auto-Injectors
5.1.3.2.3 Other Self-injectable Drug Delivery Devices
5.1.4 Other Device Types
5.2 By Therapeutic Application
5.2.1 Cardiovascular
5.2.2 Oncology
5.2.3 Autoimmune Disorder
5.2.4 Pulmonary Disease
5.2.5 Other Therapeutic Applications
5.3 By Sales Channel
5.3.1 Hospitals
5.3.2 Pharmacy
5.3.3 Other Sales Channels
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Gerresheimer AG
6.1.2 Pfizer Inc.
6.1.3 Teleflex Medical
6.1.4 Becton, Dickinson and Company
6.1.5 Teva Pharmaceutical Industries Ltd
6.1.6 Merck & Co. Inc.
6.1.7 Novartis AG
6.1.8 Biocorp
6.1.9 GSK plc
6.1.10 Baxter
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
China Drug Delivery Devices Industry Segmentation
As per the scope of the report, drug delivery devices are specialized tools for the delivery of a drug or therapeutic agent via a specific route of administration.
The China drug delivery devices market is segmented by device type (nasal (inhalers, and other device types) implantable, injectable (conventional drug delivery devices, self-injectable drug delivery devices(prefilled syringes, auto-injectors, and other self-injectable drug delivery devices)), and other device types)), therapeutic application (cardiovascular, oncology, autoimmune disorder, pulmonary disease, and other therapeutic applications), and sales channel (hospitals, pharmacy, and other sales channels).
The report offers the value (in USD million) for the above segments.
| By Device Type | ||||||||
| ||||||||
| Implantable | ||||||||
| ||||||||
| Other Device Types |
| By Therapeutic Application | |
| Cardiovascular | |
| Oncology | |
| Autoimmune Disorder | |
| Pulmonary Disease | |
| Other Therapeutic Applications |
| By Sales Channel | |
| Hospitals | |
| Pharmacy | |
| Other Sales Channels |
China Drug Delivery Devices Market Research FAQs
What is the current China Drug Delivery Devices Market size?
The China Drug Delivery Devices Market is projected to register a CAGR of 9.30% during the forecast period (2024-2029)
Who are the key players in China Drug Delivery Devices Market?
Becton, Dickinson and Company, Gerresheimer AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd and Teleflex Medical are the major companies operating in the China Drug Delivery Devices Market.
What years does this China Drug Delivery Devices Market cover?
The report covers the China Drug Delivery Devices Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the China Drug Delivery Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
China Drug Delivery Devices Industry Report
Statistics for the 2024 China Drug Delivery Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. China Drug Delivery Devices analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
